Announcement PDF Investor Presentation 15 July 2026 ASX Code: OSL Corporate Summary Share price (ASX:OSL) $1.40 Shares on Issue 30.9 million Market Capitalisation $43.3 million Cash (31 March 2026) $9.3 million Enterprise Value $34.0 million Options ASX:OSLOE ($0.90 | 30 Jun-27) 12.1 million Options ASX:OSLOD ($1.20 | 31 Jul-27) 7.7 million Top 20 Shareholders 58.4% Substantial Shareholders Pengana Capital (20.2%) Regal Partners Funds (10.4%) Australian Ethical (8.4%) Analyst Coverage Nick Lau | Dr Dennis Hulme: Taylor Collison Corporate Summary1,2 2 1. Share price, investor data as at 13 July 2026 2. Financial data per OncoSil Medical financial reports Directors / Management Share Price Graph Dr Thomas Duthy Non-Executive Chairman Nigel Lange CEO & Managing Director Lelde Smits Non-Executive Director Shelley Steyn Chief Financial Officer Renzo DiCarlo Head of Operations & Development Focus A Class III medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC) and more recently distal cholangiocarcinoma (dCCA) under a pending HDE in the US Key Product: OncoSil device (approved in 34+ countries) Breakthrough Device Designation: US, Europe + UK Commercialising targeted radiotherapy for pancreatic cancer • OncoSil Medical is commercialising the OncoSil device, an implanted device (brachytherapy) delivering targeted radiation (32P) to pancreatic tumours • OncoSil device is now approved for sale in over 34 countries via CE Mark • Commercial ramp-up has commenced in FY26, driven by significant growth in existing European markets • TGA approval received in Australia • Reached final FDA review stage for Humanitarian Device Exemption (HDE) application in the United States (US) for distal cholangiocarcinoma (dCCA) • Increasing market access via label expansion combining new delivery methods and new chemotherapy combinations1 • $2.1 million investment in new Sydney facility supports a potential $98 million revenue opportunity at ~70% Gross Margin at scale • Platform technology can be leveraged into other cancer indications (Bile duct cancer, liver, glioblastoma) • Experienced Board & Management team in the commercialisation of interventional oncology devices >US$4.2bn global addressable market3 • Granted Breakthrough designation in the EU, UK and US with extensive patent coverage across all key geographies • Large global pancreatic cancer patient population of ~510k p.a and targeting locally unresectable population of ~153k (~30%) with the market expected to increase by 37% by 20352 • Negligible survival improvement in over 20 years with <12% survival rates at 5-years and 8.5 months median overall • Existing commercial markets have an addressable total market of approximately $900 million annually • Patient recruitment completed for PANCOSIL & TRIPP-FFX trials, targeting: ✓ Percutaneous delivery to drive market access and clinical adoption globally ✓ Label expansion in addition to standard-of-care chemotherapy (FOLFIRINOX) Executive Summary References: 1. Subject to Regulatory Approval. 2. Globocan 2022 data . 3 179,000 global locally advanced pancreatic cancer population multiplied by US$24k average price 3 Significant achievements over FY26 • Patient recruitment completed for PANCOSIL study and preliminary data presented at CIRSE 2025 Congress (a groundbreaking delivery method for OncoSil device) • TRIPP-FFX trial (to expand OncoSil device label with additional chemotherapy combination) meets co-primary endpoints and initial data presented at ESMO GI 2026 Congress • OSPREY Interim results presented at ESGE Days 2026 Congress • TGA Approval received in Australia • Second manufacturing facility in Sydney, Australia activated, validation has been successfully completed, awaiting regulatory approval • US FDA confirmed all outstanding questions relating to HDE application for the treatment of dCCA have been satisfactorily addressed. Remaining documentation submitted and awaiting the approval • German Federal Joint Committee (G-BA) tender process underway to appoint a CRO • First patient treatments completed at Germany, Portugal and the UK Executive Summary (cont.) 4 Momentum achieved in late FY26 is expected to continue in FY27, which is anticipated to deliver significant regulatory, manufacturing and commercial milestones for OncoSil Medical: • Expanding market access for LAPC and dCCA patients • Facilitating new combinations of the OncoSil Device with standard chemotherapy in first-line LAPC • Facilitating new treatment delivery method for the OncoSil device • New manufacturing to simplify supply and expand margins OncoSil Device OncoSil is intended for the treatment of locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy OncoSil is a single-use brachytherapy device comprised of microparticles and a diluent OncoSil is currently implanted directly into a pancreatic tumour via injection under endoscopic ultrasound guidance 98% of all radiation is delivered within 81 days of injection causing damage to cancer cell DNA and killing malignant cancer cells with no damage to surrounding tissue Percutaneous delivery is transformational and anticipated to significantly accelerate market penetration*: ✓ Expanding the number of treating clinicians to include Interventional Radiologists ✓ Broader patient access and points of care ✓ Outpatient day procedure ✓ Conscious sedation (patient awake) Requires only one supervised procedure given simplicity and familiarity with standard, everyday, biopsy procedures Driving increased resection rates, downstaging, survival benefits and quality of life 5 Label extension with FOLFIRINOX chemotherapy*: ✓ Accelerates market penetration with label expansion to include coverage of OncoSil device in addition to standard- of-care chemotherapy (FOLFIRINOX) * Subject to regulatory approvals Reinforcing the significant unmet need for new therapeutic approaches Pancreatic Cancer Treatment Has Seen Limited Guideline Evolution 6 First-Line (Initial Therapy) LAPC Second-Line LAPC Disease Progression Disease Progression Best Supportive Care Experimental Therapies FOLFIRINOX chemotherapy (2011) Gemcitabine + nab-paclitaxel chemotherapy (2013) OncoSil device is chemotherapy agnostic; immunotherapies (mono therapy / combination therapies) have shown no survival benefit – hence, no incorporation into treatment guidelines (NCCN, ESMO) – significantly lower risk of product obsolescence Guideline recommendations have remained largely consistent across multiple annual updates, only change has been NALIRIFOX in 2024 – 10+ years after initial clinical data for other regimens NCCN – National Comprehensive Cancer Network; ESMO – European Society for Medical Oncology FOLFIRINOX chemotherapy (2011) Gemcitabine + nab-paclitaxel chemotherapy (2013) OncoSil 1st line in LAPC Growing number of active implanting centres to drive revenue momentum Expanding Commercial Footprint Across Key European Markets Germany • 2 hospitals already opened before G-BA trial • 40 new hospitals expected to start by 1H CY27 • Expecting to commence G-BA trial in 2H CY26 • Patients’ ineligible for trial may still be treated commercially provided they are candidates for OncoSilTM treatment Spain • Largest revenue-contributing market • 9 hospitals routinely ordering and treating with OncoSil • 4 new hospitals are expected to start in CY26 • Strong referral acceptance from oncologists and surgeons Italy • 5 hospitals routinely ordering and treating with OncoSil • 4 new hospitals are expected to start in CY26 • OncoSil adopted by two leading hospitals — University of Verona and San Camillo Forlanini Hospital • Revenue contribution expected to increase significantly in 2H CY26 following finalisation of individual tender agreements Turkiye • 5 hospitals routinely ordering and treating with OncoSil • 4 new hospitals are expected to start in CY26 • Cumulatively 45% resection rate in real-world setting • One of the largest potential markets in oncology and nuclear medicine treatments • Ongoing referral education initiatives to increase patient flow 7 8 12 17 20 26 31 4 5 3 6 5 27 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 10 20 30 40 50 60 70 1H CY24(A) 2H CY24(A) 1H CY25(A) 2H CY25(A) 1H CY26(A) 2H CY26(E) Commercially Active Implanting Centres Existing New G-BA Funded Study German Federal Government Funded Expected to be announced 1H FY27 ~$47 million in est. value accretion Population ~ 84 million Pancreatic Cancer Incidence p.a.1 22,587 Locally Advanced Pancreatic Cancer p.a. 6,776 Market Opportunity p.a. $264 million System-funded clinical evidence generation alongside ongoing commercial use Germany: Capital-Efficient Phase III with Commercial Momentum References: 1. Globocan 2025 data 2.https://www.aok.de/pp/hintergrund/mindestmengen/mindestmengen-transparenzkarte- 2026/ 3. The centres with appropriate nuclear medicine facilities capable of delivering OncoSilTM device The top 40 German pancreatic cancer centres performed approximately 4,400 complex pancreatic surgeries in 20242, accounting for ~40% of all such procedures nationwide. These high-volume centres represent our primary targets for commercial adoption, alongside their anticipated participation in the G-BA trial3. Abbreviation: G-BA: Gemeinsamer Bundesausschuss (Federal Joint Committee). 9 G-BA Market Opportunity 10 Est. LAPC patients within G-BA Centres (n=40) 4,400 Est. LAPC patients to be recruited into G-BA Trial1 280 1. Randomised 1:1 to the OncoSil + chemotherapy arm versus chemotherapy alone arm 2. G-BA sites are already NUB approved. No additional reimbursement approval needed to treat commercially. 4,120 Est. pool of patients potentially able to receive OncoSil outside of trial within G-BA sites (eligible for reimbursement2) $168 million (annually) Serviceable market opportunity with high sales synergies How the G-BA Initiative Accretes Significant Value in OncoSil Direct Sales Revenue Over Trial Period1 $5.6 million $6.5 million Potential ancillary commercial sales at G-BA sites over Trial Period2 $35.0 million Est. cost if OncoSil Sponsored Identical G-BA Trial Total est. value accretion $47.1 million 11 Additional Actual + Potential Intangible Benefits • Level 1 evidence trial (gold standard for regulators/clinicians) • Positive data provides National Reimbursement in Germany • Incorporation into German consensus treatment guidelines • Potential for other European consensus treatment guidelines • Important for Health Technology Assessments (HTAs) re: further reimbursement in additional markets (e.g. NICE UK, HAS France) • Significantly increases trained clinicians in Germany, driving future adoption patterns 1. At the commercial selling price per OncoSil treatment 2. Trial recruitment expected to be over a two-year period, commencing 1H CY26 Clinical Trials Two substantive studies reported both meeting primary endpoints Total investment (ex COGS) - $8.1 million Two major regulatory changes to approved label in FY27 Expanding Physician Access and Improving Procedural Economics Expanded Label to Facilitate Percutaneous Administration Preliminary results from the PANCOSIL Investigator Initiated Study, presented at the CIRSE 2025, demonstrate that CT-guided percutaneous administration of OncoSilTM is safe and feasible. Why Percutaneous Administration Matters • Expanded physician access: Broadens treating base to include Interventional Radiologists (IRs) • Compelling healthcare economics: • 10–20-minute procedure time • Outpatient setting* • Conscious sedation (no general anaesthesia) • High procedural familiarity: IRs experienced in minimally invasive, tumour-directed radiation therapies (e.g. SIR-Spheres®, TheraSphereTM, QuiremSpheres®) • Portfolio strategy: Attractive tuck-in product for surgical and interventional offerings * where permitted 1. BSI is a Notified Body under the EU Medical Device Regulation (EU MDR).That means BSI is one of the authorised independent organisations that assesses medical devices and can issue/maintain MDR certificates after a conformity assessment. The certification supports the manufacturer’s ability to apply/maintain CE marking for the device in its approved indication/scope. 13 European IR Market Dynamics > 5,000 Interventional Radiologists CAGR 7-8% into 2030 ~ 2,000 Interventional Radiologists in Germany Active Tumour Board Participation • OncoSil will file a change notification with the British Standards Institute (BSI) for its existing regulatory approval (CE Mark) in 1H FY271 • Anticipate regulatory acceptance in 2H FY27 & commence on-label marketing of OncoSil device for percutaneous patient treatment M&A Activity in the Interventional Radiology Space 14 Significant M&A Activity in IR/Interventional Oncology since 2018 Acquirer Target [Embolic Bead Business] Alicon (China) TRIPP-FFX: Positive Phase II Results Support FOLFIRINOX Label Expansion Preliminary results from the TRIPP-FFX Trial, presented at the ESMO GI 2026, demonstrated that the study met both co-primary endpoints, supporting the use of OncoSil alongside standard-of-care FOLFIRINOX chemotherapy in patients with unresectable LAPC. • OncoSil will file a change notification with the British Standards Institute (BSI) for its existing regulatory approval (CE Mark) in 1H FY271 • Anticipate regulatory acceptance in 2H FY27 & commence on-label marketing of OncoSil device in addition to standard-of-care FOLFIRINOX chemotherapy 15 Study Results • Study met both co-primary endpoints (Safety and LDCR at 16 weeks) • Median OS: 21.3 months for OncoSil + FOLFIRINOX arm; 15.6 months for FOLFIRINOX only arm1 • LDCR at 16 weeks: 85.0% for OncoSil + FOLFIRINOX arm1 • 12.5% resection rate, with 60% R0 margins1 • Manageable safety profile 1. Per protocol (PP) Analysis Commercial Implications Regulatory • Supports label expansion to include FOLFIRINOX Clinical • Validates OncoSil device alongside standard-of-care chemotherapy Market Access • Accelerates market penetration by aligning with established treatment pathways Commercial • Strengthens physician adoption and supports broader uptake of OncoSil device TRIPP-FFX: Positive Phase II Results Support FOLFIRINOX Label Expansion 16 FOLFIRINOX OncoSil device + FOLFIRINOX ITT (n=43) PP (n=41) ITT (n=45) PP (n=40) LDCR at 16 weeks * (95% CI) 86.0% (72.1–94.7) 85.4% (70.8–94.4) 82.2% (67.9–92.0) 85.0% (70.2–94.3) Best Overall Response * Partial Response Stable Disease Progressive Disease Missing 37.2% 51.2% 9.3% 2.3% 36.6% 53.7% 9.8% 0 55.6% 31.1% 8.9% 4.4% 60.0% 30.0% 10.0% 0 Surgical Resection R0 margins 11.6% 16.7% 7.3% 33% 11.1% 60% 12.5% 60% Tumour Volume, median maximal change –57.0% –55.9% –72.1% –72.2% Local PFS,* median months (95% CI) 11.8 (7.8–nc) 9.9 (7.8–nc) 12.8 (7.8–nc) 12.8 (11.2–nc) PFS,* median months (95% CI) 9.9 (7.8–nc) 9.9 (7.5–nc) 12.1 (7.8–15.1) 12.1 (7.8–15.1) Overall Survival, median months (95% CI) 15.8 (10.2–nc) 15.6 (10.2–21.0) 18.2 (13.8–nc) 21.3 (13.8–nc) Follow-Up, median months (95% CI) 12.2 (9.9–17.0) Not reached 12.4 (11.0–17.0) Not reached Initial results. * By blinded independent central review (RECIST 1.1); CI, confidence intervals; nc, non-calculable. Clinical trial insights supporting strategic investment decisions PALACROS Participation and PULSE Trial Investment Rationale What the PULSE Study Is • Study Purpose and Consortium: PULSE is a Phase II trial evaluating the OncoSil device within the PALACROS European academic consortium focused on LAPC treatment. • Study Design and Patient Population: The trial enrolls 120 patients with unresectable LAPC post- chemotherapy, comparing single versus repeat OncoSil device implantations. • Primary and Secondary Endpoints: Primary endpoint is 9 month local progression-free survival (LDCR); secondary endpoints include survival, quality of life, and safety measures. • Integration and Significance: PULSE integrates OncoSil Medical into Europe's largest pancreatic cancer research, building on earlier studies for credible multimodal therapy evidence. 17 PULSE Phase II Trial as a Value Driver • Capital-Efficient Clinical Development: OncoSil device treatments provided in-kind as part of the trial, with no other study related-costs applicable, resulting in estimated cost savings of $9 million versus an OncoSil Medical sponsored study. • Regulatory and Payer Engagement: Academic trial participation enhances evidence credibility, supporting regulatory approval and reimbursement discussions. • Commercial Upside Potential: Positive trial outcomes could increase patient treatments and revenue through broader adoption and repeat use. US FDA Approval Humanitarian Device Approval (HDE) expected in August 2026 dCCA a rare, largely untreatable cancer with poor survival Patients with dCCA have a poor prognosis with limited treatment options and survival Distal Cholangiocarcinoma (dCCA) • dCCA develops as a cancerous tumour in the common bile duct within the head of the pancreas. • Clinical symptoms of the disease are not evident until the tumour has developed to a point that it is difficult to remove with surgery. • More than 50% of patients who develop dCCA cannot have the tumour removed surgically (the tumour is “unresectable”)1. • Treatments for unresectable tumours involve the placement of a stent, chemotherapy, external radiation therapy, or a combination of the two. • Side effects due to chemotherapy and radiation therapy are considerable and have a negative impact on the quality of life for the patient. • OncoSilTM has shown considerable promise for dCCA2 and is the basis for the HDE. • The advantage of OncoSilTM is the ability to deliver a high radiation dose to the target dCCA tumour with minimal side-effects. 19 References: 1. Hester CA, Dogeas E, Augustine MM, et al. Incidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012. J Surg Oncol 2019; 119:303-317. doi: 10.1002/jso.25336 2. Ross PJ et al. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy. ESMO Open February 2022; 7 (1): 100356. HDE: Accelerating US Market Access for OncoSil in dCCA * Subject to oversight conditions standard under the HDE framework What is HDE Pathway? • Designed for medical devices targeting rare diseases affecting fewer than 8,000 individuals annually • Permits approval based on demonstration of probable benefit outweighing risk, rather than requiring the extensive clinical evidence of a costly Phase III randomised clinical trial needed for a Pre-market approval (PMA) • Provides shortened market access with a cost-efficient route Why HDE is Relevant for OncoSil in dCCA • dCCA is a rare and highly aggressive cancer with limited treatment options and poor prognosis • OncoSil device is being positioned as a novel, localized radiation treatment that may address a significant unmet need in this patient population • Under this approval, OncoSil Medical will be authorised to commercially market and sell the OncoSil device in the US* Strategic Benefit for OncoSil Medical • Reduced clinical development burden and cost (no randomised trial) • Earlier US commercial entry opportunity • Homogeneous reimbursement landscape • Shorter regulatory timeline versus PMA • Ability to generate real-world evidence and physician adoption post-approval • Establishes US market presence in a high-value oncology indication HDE Eligibility → FDA Approval → Coding & Reimbursement → Initial Commercialisation → US Adoption 20 OncoSil Advances to Final Administrative Stage Before Potential FDA HDE Approval Major Regulatory Milestone Achieved • On 3 June 2026, the FDA confirmed that all previously raised questions have been satisfactorily addressed. • Completion of the substantive review process represents the most advanced stage reached in the Company's U.S. regulatory program. Final FDA Requirements • The FDA has requested submission of: • Final device labelling for the OncoSil device – submitted 2 July • Any required updates to the proposed post-market study – submitted 2 July Clear Path to Approval • Following receipt of the requested information, the FDA indicated its intention to complete the review within 45 days and grant the HDE. • Potential HDE approval would establish OncoSil's first U.S. regulatory approval pathway. 21 Manufacturing Investment largely complete Strong economics <5% capital intensity Supports potential sales of ~$100 million at full capacity Macquarie Cyclotek site Technology & Innovation Key Milestones • Established a dedicated Australian manufacturing capability at Macquarie Park through a strategic partnership with Cyclotek. • Successfully completed three manufacturing validation cycles with Cyclotek, producing more than 50 validation doses of the OncoSil device. • Commercial production expected to commence in 2H CY2026, subject to final regulatory approval. Strategic Benefits • Scalable production platform capable of supporting increasing global commercial demand. • Capital-efficient manufacturing model combining Cyclotek's infrastructure with OncoSil-owned manufacturing equipment and proprietary process. • Greater control over product quality, manufacturing capability and supply chain resilience. • Expected to improve gross margins over time through enhanced manufacturing efficiencies. 23 Outlook Upcoming Milestones in FY27 25 1H FY27 2H FY27 • OncoSil device US label filing to FDA (HDE) • Presentation of TRIPP-FFX Clinical Trial Results at ESMO GI Congress • Completion of validation of manufacturing at Cyclotek • PALACROS European consortium | PULSE trial • G-BA funded study commencement • FDA HDE approval for distal cholangiocarcinoma (dCCA) • EU regulatory submission – percutaneous label change (PANCOSIL) • EU regulatory submission – FOLFIRINOX label change (TRIPP-FFX) • Commercial sales from OncoSil|Cyclotek manufacturing facility in Sydney* • EU regulatory approval – percutaneous label change (PANCOSIL) • EU regulatory approval – FOLFIRINOX label change (TRIPP-FFX) • Launch of OncoSil device in Australia • Launch of OncoSil device in the United States* * Subject to approvals Learn more about OncoSil Medical: • Website • ASX announcements • LinkedIn This announcement was authorised by the Board of Directors of OncoSil Medical Limited.